Company Overview

Cyanotech Corporation is a U.S.-based biotechnology and nutraceutical company specializing in the large-scale cultivation, production, and commercialization of microalgae-based products. The company operates primarily within the dietary supplements, functional foods, and natural ingredients industries, with a focus on algae-derived antioxidants and proteins. Its core products include astaxanthin and spirulina, which are sold as branded consumer supplements and as ingredients to other manufacturers.

The company’s primary revenue drivers are its flagship brands BioAstin® (astaxanthin) and Hawaiian Spirulina®, which are marketed for their antioxidant, anti-inflammatory, and nutritional properties. Cyanotech serves health-conscious consumers, dietary supplement brands, and food ingredient customers, with a unique positioning based on vertically integrated production and outdoor algae cultivation in Hawaii. Founded in 1983, the company evolved from a research-focused algae producer into a commercial manufacturer, and it became publicly traded in the 1990s, maintaining a niche but established presence in the global nutraceutical market.

Business Operations

Cyanotech operates through a single integrated business model centered on the cultivation, harvesting, processing, and sale of microalgae products. Its operations are conducted primarily at its Kona, Hawaii facility, where the company controls large open-air cultivation ponds, processing infrastructure, and quality assurance systems. Revenue is generated through direct-to-consumer sales, wholesale distribution, and bulk ingredient sales to third-party supplement and food companies.

The company’s product portfolio is derived mainly from Haematococcus pluvialis (astaxanthin) and Arthrospira platensis (spirulina). Cyanotech manages the full production lifecycle, which it positions as a competitive advantage due to traceability, quality control, and cost management. Domestic sales represent a significant portion of revenue, while international sales and ingredient exports provide additional diversification. No material joint ventures have been consistently disclosed in public filings, and operations are largely conducted through the parent company without extensive subsidiary structures.

Strategic Position & Investments

Cyanotech’s strategic direction has focused on operational efficiency, brand preservation, and selective market expansion rather than aggressive acquisition-driven growth. The company has invested in process improvements, cultivation optimization, and product quality enhancements to maintain competitiveness in the increasingly crowded natural supplements market. Management has emphasized cost control, yield improvement, and pricing discipline in response to margin pressure and global competition.

Historically, Cyanotech has not pursued large-scale acquisitions and instead relies on organic growth and long-term customer relationships. Its strategic positioning emphasizes natural production methods, U.S.-based manufacturing, and long-standing expertise in algae cultivation. While the company has monitored emerging applications of microalgae in alternative proteins and sustainable nutrition, public disclosures indicate limited capital deployment into speculative or early-stage technologies. Data inconclusive based on available public sources regarding material investments in emerging algae-based sectors beyond its core nutraceutical focus.

Geographic Footprint

Cyanotech’s headquarters and primary manufacturing operations are located in Hawaii, which provides a favorable climate for year-round algae cultivation. The company’s Kona facility represents the operational center for production, research, and quality control. This geographic concentration is central to its brand identity, particularly for Hawaiian Spirulina®, but also exposes the company to region-specific operational risks.

Commercially, Cyanotech sells products throughout North America, with additional distribution into Asia, Europe, and other international markets via distributors and ingredient customers. While international sales contribute to revenue, the company does not maintain significant overseas manufacturing assets or regional headquarters outside the United States. Its global footprint is therefore best characterized as export-oriented rather than operationally multinational.

Leadership & Governance

Cyanotech is led by an executive team with experience in biotechnology manufacturing, operations, and financial management. The company operates under a traditional public company governance structure, with oversight from a board of directors and compliance with U.S. public reporting requirements. Leadership has consistently communicated a pragmatic strategy focused on sustainability, product quality, and long-term operational viability rather than rapid expansion.

Key executives include:

• Gerald R. Cysewski, Ph.D. – President and Chief Executive Officer
• James A. Honnold – Chief Financial Officer
• Elizabeth A. Cook – Vice President of Operations
• Kirk R. Allendorf – Vice President of Sales and Marketing

Management’s stated philosophy emphasizes disciplined capital allocation, scientific credibility, and maintaining brand trust in regulated nutraceutical markets.